Amarin Corporation plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $297.6M
- Price
- $14.09
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.21%
- Volume
- 36.6K
About
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Quick stats
Shares outstanding21.1M
Computed float21.1M
Float / shares100.0%
Key info
SectorHealthcare
IndustryDrug Manufacturers - General
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000897448
Websitehttps://www.amarincorp.com
AI Summary
AI-generated1/12
standardbullishearnings
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Amarin reported Q2 2026 net revenue of $42.2 million, a 42% decrease from the prior year, primarily due to the absence of a $25 million upfront payment received from Recordati in 2025. Despite the revenue decline, the company narrowed its net loss to $7.7 million and generated positive cash flow for the third consecutive quarter.
Operating expenses fell 59% year-over-year to $27.0 million, driven by the completed $70 million cost savings initiative associated with the shift to a fully partnered international model. Cash position grew to $314.6 million, and the company remains debt-free.
In-market demand for VASCEPA/VAZKEPA increased 59% globally and 69% in Europe, while the U.S. IPE market share rose to 48%. Amarin expects cash to grow approximately 10% by year-end 2026.
Red flags
- Total revenue declined 42% year-over-year due to the absence of a prior-year upfront payment